Sunil Sharma
National Institute of Technology Hamirpur · 234 works · 9,556 citations · h-index 41
Top works
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- NCCN Guidelines Insights: Colon Cancer, Version 2.2018
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
- Rectal Cancer, Version 2.2015
- Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- Targeting Axl and Mer Kinases in Cancer
- Metastatic Colon Cancer, Version 3.2013
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
- High-Throughput Virtual Screening Identifies Novel N ′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors
- Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
- Localized Colon Cancer, Version 3.2013
- LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
- Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
- Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells